At present, available data on the efficacy of ADCs in prostate cancer favours the use of anti-PSMA ADCs linked to microtubule inhibitors, as demonstrated by an overall PSA decline rate of ≥50% in 14% of patients, as reported by Petrylak et al. [8], and in 8% of the studied population, as reported by Milowsky et al. [9]. This evidence concerns the gene FOLH1 and prostate carcinoma.